Home » Topics » Regulatory » EMA

EMA
RSS

EMA recommends marketing suspension for meprobamate-containing medicines

Jan. 23, 2012

EMA reviews Gilenya following reports of heart problems in patients

Jan. 23, 2012

Novartis announces CHMP opinion on Signifor

Jan. 23, 2012

CHMP issues opinion on Folotyn

Jan. 23, 2012

EMA validates MAA for single-tablet HIV-1 therapy

Dec. 23, 2011

Roche's Zelboraf receives CHMP opinion

Dec. 21, 2011

CHMP issues recommendation on marketing authorization Esmya

Dec. 21, 2011

Vertex gives update on Kalydeco NDA and MAA

Dec. 20, 2011

EMA approves combination antimalarial drug Eurartesim

Dec. 2, 2011

EMA committee recommends approval of new indication for Herceptin

Nov. 23, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...